Company profile: ProCure
1.1 - Company Overview
Company description
- Provider of a network of proton therapy centers in the United States, offering proton therapy including pencil beam scanning; physician case evaluations; initial consultation and planning; treatment sessions typically 5 days a week for 4–7 weeks; and regular radiation oncologist check-ins.
Products and services
- Case Evaluation: Physician-reviewed assessment by a review board determines suitability for proton therapy, providing eligibility decisions before treatment planning
- Pencil Beam Scanning: High-precision advanced technique uses an ultra-narrow radiation beam to target tumors layer by layer, enhancing accuracy and reducing risk to surrounding healthy tissue
- Proton Therapy: Precision-guided radiation treatment delivers radiation directly into the tumor, minimizing exposure to surrounding healthy tissue and reducing side effects during care
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to ProCure
Ventana
HQ: United States
Website
- Description: Provider of tissue-based diagnostic solutions, medical diagnostic systems, and biopsy-based cancer tests. Offers pathology lab instruments, cytology and tissue-based assays, and software for anatomic pathology labs; point-of-care coagulation monitoring; in-vitro diagnostics for clinical chemistry, immunochemistry, PCR, and mass spectrometry; biotech raw materials and QC kits; and non-invasive prenatal screening.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ventana company profile →
Adze Biotech
HQ: United States
Website
- Description: Provider of pre-clinical oncolytic immunotherapies for cancer, including a chimeric adenoviral platform for systemic delivery of immune-stimulatory transgenes and checkpoint inhibitors to distant and local tumors. Pipeline includes Adze-1.17, which selectively kills tumor cells and releases tumor-derived antigens; Adze-1.17-CD40L for malignant glioma; and Ad657, a recombinant adenovirus with intratumoral and systemic potential across broad malignancies and solid tumor indications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Adze Biotech company profile →
Calistoga Pharmaceuticals
HQ: United States
Website
- Description: Provider of therapeutic oral medicines targeting selected isoforms of the PI3K pathway to improve the health of patients with cancer and inflammatory diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Calistoga Pharmaceuticals company profile →
JW Holdings
HQ: South Korea
Website
- Description: Provider of prescription drugs, over-the-counter drugs, and medical equipment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full JW Holdings company profile →
BiPar Sciences
HQ: United States
Website
- Description: Provider of PARP inhibitor-based cancer therapies, developing BSI-201, an experimental PARP inhibitor in mid-stage trials for advanced breast cancer, ovarian cancer, and other tumors; based in Brisbane, CA.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BiPar Sciences company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for ProCure
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to ProCure
2.2 - Growth funds investing in similar companies to ProCure
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for ProCure
4.2 - Public trading comparable groups for ProCure
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →